CDK9 and plasma cell myeloma: Here, we observed that addition to inducing cell death, CDK9 inhibitors promoted the anti-myeloma activity of both proteasome inhibitors as well as BH3-mimetics, and that these effects were observed in both bortezomib-sensitive or -resistant cells.